Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China.Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongfu Cai, Baohua Xu, Na Li, Bin Zheng, Zhiwei Zheng, Maobai Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	cost-effectiveness esophageal cancer esophageal squamous cell carcinoma chemotherapy camrelizumab Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/62b150a21fe0483b9cc46b7ff0fa3956
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62b150a21fe0483b9cc46b7ff0fa3956
record_format	dspace
spelling	oai:doaj.org-article:62b150a21fe0483b9cc46b7ff0fa39562021-11-16T04:50:27ZCost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma1663-981210.3389/fphar.2021.732912https://doaj.org/article/62b150a21fe0483b9cc46b7ff0fa39562021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.732912/fullhttps://doaj.org/toc/1663-9812Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China.Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity and probability sensitivity analyses were performed to test the stability of the model.Results: Treatment of esophageal squamous cell carcinoma with camrelizumab added 0.36 QALYs and resulted in an incremental cost of $1,439.64 compared with chemotherapy, which had an ICER of $3,999 per QALY gained. The ICER was far lower than the threshold of willingness to pay for one time the GDP per capita in China. Sensitivity analysis revealed that the ICERs were most sensitive to the cost of drugs, but the parameters did not have a major effect on the results of the model.Conclusion: Camrelizumab is likely to be a cost-effective option compared with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. This informs patient selection and clinical path development.Hongfu CaiBaohua XuNa LiBin ZhengZhiwei ZhengMaobai LiuFrontiers Media S.A.articlecost-effectivenessesophageal canceresophageal squamous cell carcinomachemotherapycamrelizumabTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cost-effectiveness esophageal cancer esophageal squamous cell carcinoma chemotherapy camrelizumab Therapeutics. Pharmacology RM1-950
spellingShingle	cost-effectiveness esophageal cancer esophageal squamous cell carcinoma chemotherapy camrelizumab Therapeutics. Pharmacology RM1-950 Hongfu Cai Baohua Xu Na Li Bin Zheng Zhiwei Zheng Maobai Liu Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
description	Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China.Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity and probability sensitivity analyses were performed to test the stability of the model.Results: Treatment of esophageal squamous cell carcinoma with camrelizumab added 0.36 QALYs and resulted in an incremental cost of $1,439.64 compared with chemotherapy, which had an ICER of $3,999 per QALY gained. The ICER was far lower than the threshold of willingness to pay for one time the GDP per capita in China. Sensitivity analysis revealed that the ICERs were most sensitive to the cost of drugs, but the parameters did not have a major effect on the results of the model.Conclusion: Camrelizumab is likely to be a cost-effective option compared with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. This informs patient selection and clinical path development.
format	article
author	Hongfu Cai Baohua Xu Na Li Bin Zheng Zhiwei Zheng Maobai Liu
author_facet	Hongfu Cai Baohua Xu Na Li Bin Zheng Zhiwei Zheng Maobai Liu
author_sort	Hongfu Cai
title	Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_short	Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_full	Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_fullStr	Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_full_unstemmed	Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_sort	cost-effectiveness analysis of camrelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/62b150a21fe0483b9cc46b7ff0fa3956
work_keys_str_mv	AT hongfucai costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT baohuaxu costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT nali costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT binzheng costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT zhiweizheng costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma AT maobailiu costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma
_version_	1718426727327203328

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Ejemplares similares